Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position. VRTX's diversified pipeline includes cystic fibrosis treatment, Vanzacaftor Triple, and the non-opioid pain management drug Suzetrigine, both with PDUFA dates expected in January 2025. Positioning the company for substantial future growth. The potential approvals of Vanza Triple will reinforce the Company's leadership in CF, while Suzetrigine's and the NOPAIN Act in 2025 will facilitate its entry into the lucrative pain management market.

Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis Treatment

There's a simple explanation for Vertex's glaring Q2 loss. The company raised its full-year product revenue guidance.

Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer, President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer. Susie Lisa - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Jessica Fye - J.P.

Vertex Pharmaceuticals, Inc. (VRTX) Q2 2024 Earnings Call Transcript

Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago.

Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates

Vertex stock fell late Thursday after the company reported light sales and wide losses. But the company boosted its outlook for the year.

Vertex Slumps As Guidance Hike — Featuring The Gene-Editing Launch — Fails To Erase Losses

Vertex Pharmaceuticals raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments.

Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2024, and raised its full year product revenue guidance to $10.65 to $10.85 billion. “Vertex delivered another strong quarter of revenue growth coupled with outstanding execution across the business, and we are increasing our full year product revenue guidance,” said Reshma Kewalramani, M.D., Chief Executive Officer, and President of Ver.

Vertex Reports Second Quarter 2024 Financial Results

Toast

Investing cash in great businesses can set your portfolio up for long-term success. Vertex is paving a profitable path from a portfolio of existing and likely blockbusters.

Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever

Amgen

Gilead Sciences

In the bustling world of biotechnology, innovation remains the cornerstone of growth. Some biotech stocks, known for their groundbreaking research and rapid adaptation to health challenges, are particularly well-positioned to do well in the future.

The Top 3 Biotech Stocks to Buy Now Summer 2024

Biogen

GlaxoSmithKline

Moderna

Regeneron Pharmaceuticals

Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Arcadia Biosciences

LOS ANGELES--(BUSINESS WIRE)--Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration.

Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for suzetrigine, an investigational, oral, selective NaV1.8 pain signal inhibitor to treat moderate-to-severe acute pain. Suzetrigine has the potential to be the first new class of medicine to treat acute pain in over twenty years. The FDA has granted suzetrigine priority review and assigned a Prescrip.

Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain

Bristol-Myers

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?

BMY vs. VRTX: Which Stock Should Value Investors Buy Now?

Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Curious about Vertex (VRTX) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Vertex's dominance in the cystic fibrosis drug market could be challenged. Even in the worst-case scenario, its challenger's products won't be launched soon.

Is Vertex Pharmaceuticals' Monopoly in Danger?

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $490.80, denoting a +0.1% change from the preceding trading day.

Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts

Arcutis Biotherapeutics

Axsome Therapeutics

ImmunityBio

Madrigal Pharmaceuticals

Intellia Therapeutics

Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.

7 Biotech Stocks to Keep on Your Clinical Radar

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $495.91, indicating a +0.88% shift from the previous trading day.

Here's Why Vertex Pharmaceuticals (VRTX) Gained But Lagged the Market Today

Beam Therapeutics

CRISPR Therapeutics

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.

3 Gene Editing Stocks Shaping the Future of Medicine

Intuitive Surgical

Exxon Mobil

U.S. M2 money supply has done something that no one has witnessed since the Great Depression. Meanwhile, the benchmark S&P 500 is at one of its priciest valuations in history.

2 Historically Flawless Metrics Suggest the Stock Market Can Plunge: Here Are 3 Stocks I've Sold Ahead of What May Be a Big Move for Wall Street

NeuroOne Medical Technologies Corp

Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it's extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year.

The 3 Best Neuroscience Biotech Stocks to Buy Now

Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.

3 Gene Editing Stocks That Could Grow Your Wealth

ADMA Biologics

Halozyme Therapeutics

Jazz Pharmaceuticals

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.

Add These 5 Hot Biotech Stocks In July

ASML Hld

EssilorLuxottica SA

NVIDIA

SAP SE

ASML, SAP, Nvidia, Vertex and EssilorLuxxottica are included in this Analyst Blog.

News for Vertex Pharmaceuticals Stock (VRTX)